Just a day or so late 😂

Check out that KM curve for SANO-1 trial of EsoCa (SCC or Adeno) with cCR after CRT randomized to surgery or active surveillance

🔥Non-inf OS and ⬆️QoL with AS

SANO-2 and ESOSTRATE will clarify further
rb.gy/t8j2ep
rb.gy/y3bjbw

Thx the Radiosurgery Society for the invite to present at this session focusing on GRID and FLASH!

#radonc : tons of physics, preclinical, and early clinical work going on. We need to get moving on clinical trials and translational efforts to understand how GRID and FLASH could help our patients

I remember seeing a frame vs frameless debate as a resident in a GKRS-heavy program. I went into it thinking, 'how could anyone do this without a frame?' and came out thinking 'yeah you really don't need a frame for most things.'

GOOD LUCK, WOODY!

Freddy E Escorcia (@freddyeescorcia elsewhere)
With re to your #radonc history query...I guess now is as good a time as any to turn this aging powerpoint into a twitter thread... (1/n)

We are so excited to welcome Liza and Jyotsna to UNC rad onc. Such wonderful news to see you both joining us. 🩵🩵 Happy match day to all! @jyonat1626 Ashley Weiner Shekinah Elmore, MD, MPH

Threw a party in clinic with Colette Shen as we turn approximately 30 years old! Happy birthday to us!

Someone I’ve been supporting for two years sent me this message today.

I wasn’t prepared to be so overcome with emotion. I feel as elated as the day I received the same email 🥳

Congrats to everyone who matched today and to the people who stood behind them! #MedEd #Match2024

“HCC ya again” is a much better title than ours. Thank you, QuadShot News, for highlighting our study. We’ll have to consult with you clever people on the title of our next paper.

quadshotnews.com/hcc-ya-again/

Pts with #HCC frequently face several lesions at once or over time. Our experience using ablative RT ☢️ on multiple lesions shows excellent outcomes & safety ✅

We're prospectively gathering toxicity data & PROs to validate these findings. More here:

tinyurl.com/yw8t8exa

“Daddy, it fits so I don’t think this is actually against the rules”

Pretty sure I’m raising a future white collar criminal.

For anyone who has had their end-of-life patient sitting in the ED next to someone having a drug-induced freak out, this is a no-brainer.

James, this is great stuff, thanks for sharing!

In this open-label, single-arm, phase 2

HCC patients+ PVTT -> sintilimab+bevacizumab+Radiotherapy (30-50 Gy/10 fractions)

🔺ORR 58.7%
🔺Disease control rate 100%

After median follow-up of 26 months
🔻Median OS 24 months
🔻Median PFS 13.8 months

journals.lww.com/hep/abstract/9……

For anyone else mourning the loss of Calibri.

Credit: Ellecordova on IG

This is so good. UNC Department of Radiation Oncology residents, consider this pre-rotation required reading!

What a pleasure to provide an update on our project to the esteemed group at BCLC GROUP led by Maria Reig

Huge honor to present to BCLC GROUP with Andrew Moon. We provide an update on this important collaboration to define the role of EBRT in #HCC .

Thank you for the invitation Maria Reig Meritxell Mollà IDIBAPS Hospital Clínic CIBERehd

Awesome work by Ted Yanagihara, MD, PhD and team!

A needed step forward to fully understand the role of SBRT for liver cancer. The first output of Andrew Moon stay to team up with Maria Reig at the BCLC. Terrific network with leading experts in the field. More to come.Hospital Clínic IDIBAPS

sciencedirect.com/science/articl…